Company Encyclopedia
View More
name
CR Sanjiu
000999.SZ
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People’s Republic of China and internationally. The company offers health consumer products (CHC), including cold, skin, gastrointestinal, cough, orthopedics, pediatrics drugs, and dietary nutritional supplements; and prescription drug products, such as anti-tumor, cardiovascular and cerebrovascular, digestive system, orthopedics, pediatrics, anti-infection, and other treatment areas; Chinese medicine health products; and vitamins, minerals, protein powder, collagen, probiotics, health foods, and formula granules. It also provides related health services.
3.157 T
000999.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking7/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE13.26%B
    • Profit Margin9.25%B
    • Gross Margin54.18%B
  • Growth ScoreB
    • Revenue YoY15.43%B
    • Net Profit YoY-19.04%D
    • Total Assets YoY38.74%A
    • Net Assets YoY43.41%A
  • Cash ScoreB
    • Cash Flow Margin1081.64%B
    • OCF YoY15.43%B
  • Operating ScoreB
    • Turnover0.61B
  • Debt ScoreB
    • Gearing Ratio33.92%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CR Sanjiu: CHINARES PHARMA's pediatric tranquilizer and brain supplement granules have received implied approval for clinical trials

    China Resources Pharmaceutical announced that its subsidiary, CR Sanjiu, has obtained implied permission for clinical trials of its pediatric calming and brain-nourishing granules. This product was jointly developed by CR Sanjiu, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen Institute for Drug Inspection and Research, and Shenzhen Traditional Chinese Medicine Manufacturing Innovation Center. It is classified as a Category 1.1 new drug in traditional Chinese medicine, intended for children with tic disorders due to spleen deficiency and phlegm accumulation, as well as wind-phlegm disturbance. The company expects that obtaining this implied permission for clinical trials will help further enrich its product line and enhance the market competitiveness of its products

    AASTOCKS·
    SZ
    000999
    +0.21%
    HK
    03320
    -1.45%
    AASTOCKS·
    SZ
    000999
    +0.21%
    HK
    03320
    -1.45%

    The morning session of the 2025 National Conference opens: CR Sanjiu and YILING PHARMACEUTICAL enter the arena, negotiations on traditional Chinese medicine varieties begin

    According to reporters from the on-site negotiations for the 2025 National Medical Insurance Directory and the price negotiations for innovative drugs with commercial insurance, the process for the fourth day of the 2025 national negotiations began around 8 a.m. Representatives from pharmaceutical companies such as CR Sanjiu, Jianmin Pharmaceutical, Beijing YILING PHARMACEUTICAL, Eisai, and Kereis Pharmaceuticals entered the venue in succession to await negotiations. Representatives from traditional Chinese medicine companies entered in large numbers, and negotiations for traditional Chinese medicine varieties are expected to begin

    Zhitong·
    SZ
    002603
    +0.06%
    SZ
    000999
    +0.21%
    Zhitong·
    SZ
    002603
    +0.06%
    SZ
    000999
    +0.21%

    China Resources Pharmaceutical's subsidiary CR Sanjiu earned 2.899 billion yuan in the first three quarters, a decline of 10.6%

    China Resources Pharmaceutical announced that its subsidiary CR Sanjiu achieved an operating income of RMB 21.986 billion in the third quarter, an increase of 11.4% year-on-year. It recorded a net profit of RMB 2.899 billion, a decline of 10.6%

    AASTOCKS·
    SZ
    000999
    +0.21%
    AASTOCKS·
    SZ
    000999
    +0.21%

    CR Sanjiu Reports Revenue Growth Amid Profit Decline in 2025 Q3

    China Resources Pharmaceutical Group Ltd. (HK:3320) reported a revenue increase to RMB 21.99 billion for the nine months ending September 30, 2025, up from RMB 19.74 billion, despite a net profit decline to RMB 2.90 billion from RMB 3.24 billion. The financial results indicate a decrease in cash and cash equivalents, alongside a rise in total assets and liabilities. Analysts rate the stock as a Hold with a price target of HK$5.50. The company operates in the pharmaceutical sector and has a market cap of HK$30.6 billion.

    Tip Ranks·
    SZ
    000999
    +0.21%
    Tip Ranks·
    SZ
    000999
    +0.21%

    CHINARES PHARMA: CR Sanjiu's net profit for the first three quarters is approximately 2.899 billion yuan, a year-on-year decrease of 10.65%

    According to the Zhitong Finance APP, CR Sanjiu announced its performance for the first three quarters of 2025, with total operating revenue of approximately 21.986 billion yuan, a year-on-year increase of 11.38%; net profit of approximately 2.899 billion yuan, a year-on-year decrease of 10.65%

    Zhitong·
    SZ
    000999
    +0.21%
    HK
    03320
    -1.45%
    Zhitong·
    SZ
    000999
    +0.21%
    HK
    03320
    -1.45%
    © 2025 Longbridge｜Disclaimer